-
公开(公告)号：US20210395695A1
公开(公告)日：2021-12-23
申请号：US17283942
申请日：2019-12-20
Inventor： Eun-Mi Kim , Ki-Suk Kim , Hyang-Ae Lee
IPC: C12N5/071 , C12M3/00 , C12N5/0786
Abstract: The present invention relates to a method for fabrication of a three-dimensional lung organoid comprising human stem cell-derived alveolar macrophages. Specifically, a lung organoid is fabricated by co-culturing cells not expressing the definitive endoderm marker CRCX4 according to a fabrication method of the present disclosure. The lung organoid comprises type 1 and type 2 alveolar epithelial cells as well as alveolar macrophages and realizes infectious or inflammatory responses unlike conventional lung organoids that contain no immune cells and as such, can be advantageously used in studying mechanisms of related lung diseases, excavating biomarkers, developing therapeutic agents, and so on.
-
公开(公告)号：US11446384B2
公开(公告)日：2022-09-20
申请号：US16482444
申请日：2019-03-12
Applicant: Korea Research Institute of Chemical Technology , Korea Advanced Institute of Science and Technology
Inventor： Ki-Suk Kim , Hyang-Ae Lee , Sun Hyun Park , Haeshin Lee , Mikyung Shin
Abstract: The present invention relates to a heart targeting agent comprising tannic acid, in which the agent aids a heart disease therapeutic drug to be delivered to the heart and bind to the cardiac myocardium by inducing tannylation of the drug so as to make heart targeting and accumulation of the drug possible. Unlike the conventional invasive method used for the traditional drugs to be able to target the heart, the agent of the present invention can help a drug to target the heart with high efficiency just via non-invasive intravenous administration.
-
公开(公告)号：US12173325B2
公开(公告)日：2024-12-24
申请号：US17283942
申请日：2019-12-20
Inventor： Eun-Mi Kim , Ki-Suk Kim , Hyang-Ae Lee
IPC: C12N5/071 , C12M3/00 , C12N5/0786
Abstract: The present invention relates to a method for fabrication of a three-dimensional lung organoid comprising human stem cell-derived alveolar macrophages. Specifically, a lung organoid is fabricated by co-culturing cells not expressing the definitive endoderm marker CRCX4 according to a fabrication method of the present disclosure. The lung organoid comprises type 1 and type 2 alveolar epithelial cells as well as alveolar macrophages and realizes infectious or inflammatory responses unlike conventional lung organoids that contain no immune cells and as such, can be advantageously used in studying mechanisms of related lung diseases, excavating biomarkers, developing therapeutic agents, and so on.
-
-
Search Results
3
records
(took 0.014 seconds)
